(S)-3-(2-ethylphenoxy)propane-1,2-diol | 1092799-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)-3-(2-ethylphenoxy)propane-1,2-diol
• 英文别名: (2S)-3-(2-ethylphenoxy)propane-1,2-diol
• CAS: 1092799-92-2
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: KLIWBPMQXVJEAN-JTQLQIEISA-N

物化性质

• 熔点：
  68-70 °C(Solv: hexane (110-54-3))
• 沸点：
  349.3±27.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-(2-ethylphenoxy)propane-1,2-diol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以51.8%的产率得到(S)-1-(2'-ethylphenoxy)-2,3-epoxypropane
  参考文献：
  名称：

  Synthesis of all of the stereoisomers of β3-adrenoceptor antagonist SR 59230 based on the spontaneous resolution of 3-(2-ethylphenoxy)propane-1,2-diol

  摘要：

  Racemic 3-(2-ethylphenoxy)propane-1,2-diol 2 has been effectively resolved into (S)- and (R)-enantiomers by a preferential crystallization procedure. Non-racemic diols 2, obtained via a Mitsunobu reaction, have been converted into the non-racemic 1,2-epoxy-3-(2-ethylphenoxy)propanes (S)- and (R)-5 and then into non-racemic 3-(2-ethylphenoxy)-1(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanols 1. The characteristics of all four stereoisomers, (S,S)-1 (SR 59230), (R,R)-1 (SR 59483), (R,S)-1 and (S,R)-1 (SR 59231) and their hydrogen oxalates with a 1:1 composition have been presented. The crystalline oxalates (S,S)-1 center dot C2H2O4 (SR 59230A) and (R,S)-1 center dot 0.5C(2)H(2)O(4) were studied by single crystal X-ray diffraction. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2016.05.001
• 作为产物：
  描述：

  乙基苯酚 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 4.67h， 生成 (S)-3-(2-ethylphenoxy)propane-1,2-diol
  参考文献：
  名称：

  一系列均匀取代的苯基甘油醚中的三种不同类型的手性驱动结晶。

  摘要：

  七个手性芳基甘油醚2-RC（6）H（4）-O-CH（2）CH（OH）CH（2）OH（R ​​= H，Me，Et，烯丙基，n-Pr，i-Pr，叔-Bu）以外消旋和垢的形式合成。测量了每个物种的外消旋和尺度样品的红外光谱，熔点和熔融焓，导出了液态混合的对映异构体的熵和外消旋化合物形成的Gibbs自由能，并重建了二元相图。整个家族。对这四种物质的固态外消旋化合物稳定性进行了排名。建立了注册手性药物美芬素及其乙基类似物的自发拆分。在叔丁基衍生物的溶液结晶过程中，形成了亚稳态异常聚集体，形成了在晶胞中具有三个独立的R *和一个独立的S *分子的晶体。

  DOI：

  10.1002/chir.20648

文献信息

• A Smart Library of Epoxide Hydrolase Variants and the Top Hits for Synthesis of (<i>S</i>)-β-Blocker Precursors
  作者：Xu-Dong Kong、Qian Ma、Jiahai Zhou、Bu-Bing Zeng、Jian-He Xu

  DOI：10.1002/anie.201402653

  日期：2014.6.23

  the enzyme active pocket has led to a smart library of epoxide hydrolase variants with an expanded substrate spectrum covering a series of typical β‐blocker precursors. Improved activities of 6‐ to 430‐fold were achieved by redesigning the active site at two predicted hot spots. This study represents a breakthrough in protein engineering of epoxide hydrolases and resulted in enhanced activity toward

  酶活性口袋的微调已形成了环氧水解酶变体的智能库，其底物光谱范围扩大，涵盖了一系列典型的β-受体阻滞剂前体。通过在两个预计的热点上重新设计活动站点，可以将活动提高6到430倍。这项研究代表了环氧化物水解酶蛋白质工程的一项突破，并提高了对庞大底物的活性。
• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20180186801A1

  公开（公告）日：2018-07-05

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
• US9957271B2
  申请人：——

  公开号：US9957271B2

  公开（公告）日：2018-05-01